{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:52:11Z","timestamp":1789617131883,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"European Commission Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["875171"],"award-info":[{"award-number":["875171"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2025.09.039","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:46:44Z","timestamp":1758955604000},"page":"59.e1-59.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient-Reported Outcomes of CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients and Their Impact on Survival"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-6021","authenticated-orcid":false,"given":"Anne Mea","family":"Spanjaart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-8092","authenticated-orcid":false,"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Maucort-Boulch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-8861","authenticated-orcid":false,"given":"Sylvain","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-0495","authenticated-orcid":false,"given":"Vanessa","family":"Beijamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8847-519X","authenticated-orcid":false,"given":"Am\u00e1ria","family":"Vledder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-2450","authenticated-orcid":false,"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2025.09.039_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2025.09.039_bib0002","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.039_bib0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.039_bib0004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"10.1016\/j.jtct.2025.09.039_bib0005","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/cancers15174334","article-title":"The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands","volume":"15","author":"Spanjaart","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2025.09.039_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.jtct.2025.09.039_bib0007","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2025.09.039_bib0008","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.jtct.2025.09.039_bib0009","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jtct.2025.09.039_bib0010","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.039_bib0011","doi-asserted-by":"crossref","first-page":"e802","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review","volume":"6","author":"Efficace","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.039_bib0012","first-page":"2401","article-title":"Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress","volume":"109","author":"Tchernonog","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.039_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.039_bib0014","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.039_bib0015","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.09.039_bib0016","article-title":"Use of patient-reported outcomes in risk prediction model development to support cancer care delivery: a scoping review","volume":"8","author":"Paudel","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.039_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069090","article-title":"Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study","volume":"13","author":"Vinke","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtct.2025.09.039_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.09.039_bib0019","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.09.039_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/147176","article-title":"The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: the functional assessment of cancer therapy-lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.039_bib0021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience","volume":"28","author":"Yost","year":"2005","journal-title":"Eval Health Prof"},{"issue":"32","key":"10.1016\/j.jtct.2025.09.039_bib0022","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"30","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.039_bib0023","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.039_bib0024","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.039_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2023.283162","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","volume":"109","author":"Gordon","year":"2024","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.039_bib0026","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.jtct.2025.09.039_bib0027","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.09.039_bib0028","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1002\/hem3.72","article-title":"Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?","volume":"8","author":"Perthus","year":"2024","journal-title":"Hemasphere"},{"issue":"17","key":"10.1016\/j.jtct.2025.09.039_bib0029","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cam4.4692","article-title":"Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: analysis of 1239 patients from the GOYA study","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.039_bib0030","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1634\/theoncologist.2019-0348","article-title":"The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the \"Real-World\": results from the population-based PROFILES registry","volume":"25","author":"Husson","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.039_bib0031","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.039_bib0032","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.09.039_bib0033","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1016\/S1470-2045(24)00256-0","article-title":"Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies","volume":"25","author":"Khatsuria","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.039_bib0034","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1200\/OP.22.00501","article-title":"Development of a core set of patient- and caregiver-reported signs and symptoms to facilitate early recognition of acute chimeric antigen receptor T-cell therapy toxicities","volume":"19","author":"Spanjaart","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.039_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11136-024-03810-0","article-title":"Health-related quality of life dynamics: modelling insights from immunotherapy","volume":"34","author":"Hasgul","year":"2024","journal-title":"Qual Life Res"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:59:19Z","timestamp":1773255559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666636725014629"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.039","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes of CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients and Their Impact on Survival","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}